to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
Oral rivaroxaban for symptomatic venous thromboembolism.
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Idraparinux versus standard therapy for venous thromboembolic disease.
Extended prophylaxis of venous thromboembolism with idraparinux.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Oral anticoagulants: new and improved.
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.